Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective | Zendy

Michael K. Racke | Zendy; Amy E. LovettRacke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective

Author(s) -

Michael K. Racke,

Amy E. LovettRacke

Publication year - 2011

Publication title -

the journal of immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.737

H-Index - 372

eISSN - 1550-6606

pISSN - 0022-1767

DOI - 10.4049/jimmunol.1090138

Subject(s) - glatiramer acetate , multiple sclerosis , experimental autoimmune encephalomyelitis , medicine , encephalomyelitis , relapsing remitting , immunology , pharmacology

Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the United States since 1996. It is currently one of two first-line agents for use in the treatment of relapsing-remitting MS. GA was the first agent to be used in the treatment of MS that was developed using the animal model of MS called experimental autoimmune encephalomyelitis. In this commentary, we examine the development of GA as a treatment for MS and discuss its mechanism of action as suggested by recent studies using modern immunologic methods.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research